2012 Update in addiction medicine for the generalist

Addiction Science & Clinical Practice

Adam J Gordon²  Alexander Y Walley⁵  Jeanette M Tetrault¹  Hillary V Kunins⁴  Darius A Rastegar³ 

[1]Yale University School of Medicine, New Haven, CT, USA

[2]University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA

[3]Johns Hopkins School of Medicine, Baltimore, MD, USA

[4]Montefiore Medical Center/Albert Einstein College of Medicine, Queens, NY, USA

[5]Boston University School of Medicine, Boston, MA, USA

关键词: Screening and brief intervention;    Substance-related disorders;    Drug abuse;    Addictive behavior;    Alcoholism;    Primary care;   

Others  :  789313
DOI  :  10.1186/1940-0640-8-6

 received in 2012-09-16, accepted in 2013-03-07,  发布年份 2013

【 摘 要 】

This article presents an update on addiction-related medical literature for the calendar years 2010 and 2011, focusing on studies that have implications for generalist practice. We present articles pertaining to medical comorbidities and complications, prescription drug misuse among patients with chronic pain, screening and brief interventions (SBIs), and pharmacotherapy for addiction.

【 授权许可】

   
2013 Rastegar et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gordon AJ, Sullivan LE, Alford DP, Arnsten JH, Gourevitch MN, Kertesz SG: Update in addiction medicine for the generalist. J Gen Intern Med 2007, 22:1190-1194.
• [2]Gordon AJ, Fiellin DA, Friedmann PD, Gourevitch MN, Kraemer KL, Arnsten JH, Saitz R, on behalf of the Society of General Internal Medicine’s Substance Abuse Interest Group: Update in addiction medicine for the primary care clinician. J Gen Intern Med 2008, 23:2112-2116.
• [3]Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley AY: Update in addiction medicine for the generalist. J Gen Intern Med 2011, 26:77-82.
• [4]Brick J: Medical consequences of acute and chronic alcohol abuse. In Handbook of the Medical Consequences of Alcohol and Drug Abuse. 2nd edition. Edited by Brick J. New York, NY: Haworth Press; 2008:9-38.
• [5]Gordon AJ, Gordon JM, Carl K, Hilton MT, Striebel J, Maher M: Physical Illness and Drugs of Abuse: A Review of the Evidence. New York, NY: Cambridge University Press; 2010.
• [6]Saitz R: Medical and surgical complications of addiction. In Principles of Addiction Medicine. 4th edition. Edited by Ries RK, Fiellin DA, Miller SC, Saitz R. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:945-967.
• [7]Nace EP: Alcohol. In Clinical Textbook of Addictive Disorders. 3rd edition. Edited by Frances RJ, Miller SI, Mack AH. New York, NY: Guilford Press; 2005:75-104.
• [8]Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK: Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med 2011, 26:162-169.
• [9]Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y: Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2011, 57:427-436.
• [10]Ruidavets JB, Ducimetière P, Evans A, Montaye M, Haas B, Bingham A: Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ 2010, 341:c6077.
• [11]Eyer F, Schuster T, Felgenhauer N, Pfab R, Strubel T, Saugel B: Risk assessment of moderate to severe alcohol withdrawal—predictors for seizures and delirium tremens in the course of withdrawal. Alcohol Alcohol 2011, 46:427-433.
• [12]Rangel C, Shu RG, Lazar LD, Vittinghoff E, Hsue PY, Marcus GM: Beta-blockers for chest pain associated with recent cocaine use. Arch Intern Med 2010, 170:874-879.
• [13]Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ: Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990, 112:897-903.
• [14]McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, on behalf of the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology: Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008, 117:1897-1907.
• [15]Liebschutz JM, Saitz R, Weiss RD, Averbuch T, Schwartz S, Meltzer EC: Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 2010, 11:1047-1055.
• [16]Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ: Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010, 152:712-720.
• [17]Paulozzi LJ, Kilbourne EM, Desai HA: Prescription drug monitoring program and death rates from drug overdose. Pain Med 2011, 12:747-754.
• [18]Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, on behalf of the American Pain Society/American Academy of Pain Medicine Opioids Guidelines Panel: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
• [19]Federation of State Medical Boards of the United States: Model policy for the use of controlled substances for the treatment of pain. www.fsmb.org/pdf/2004_grpol_controlled_substances.pdf webcite
• [20]Centers for Disease Control and Prevention (CDC): CDC grand rounds: prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012, 61:10-13.
• [21]Morasco BJ, Corson K, Turk DC, Dobscha SK: Association between substance use disorder status and pain related function following 12 months of treatment in primary care patients with musculoskeletal pain. J Pain 2011, 12:352-359.
• [22]Dobscha SK, Corson K, Perrin NA, Hanson GC, Leibowitz RQ, Doak MN: Collaborative care for chronic pain in primary care: a cluster randomized trial. JAMA 2009, 301:1242-1252.
• [23]Gordon AJ, Alford DP: Screening, brief intervention, and referral to treatment (SBIRT) curricular innovations: addressing a training gap. Subst Abuse 2012, 33:227-230.
• [24]US National Institute on Drug Abuse (NIDA): Minutes of the 101st meeting of the National Advisory Council on Drug Abuse. http://archives.drugabuse.gov/about/organization/nacda/minutes101st.html webcite
• [25]US National Institute on Alcohol Abuse and Alcoholism (NIAAA): Screening and brief intervention. Part II - a focus on specific settings. http://pubs.niaaa.nih.gov/publications/arh28-2/toc28-2.htm webcite
• [26]Desy PM, Perhats C: Alcohol screening, brief intervention, and referral in the emergency department: an implementation study. J Emerg Nurs 2008, 34:11-19.
• [27]Brooker C, Peters J, McCabe C, Short N: The views of nurses to the conduct of a randomised controlled trial of problem drinkers in an accident and emergency department. Int J Nurs Stud 1999, 36:33-39.
• [28]Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R: A single-question screening test for drug use in primary care. Arch Intern Med 2010, 180:1155-1160.
• [29]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 2000.
• [30]Skinner HA: The Drug Abuse Screening Test. Addict Behav 1982, 7:363-371.
• [31]Bradley KA, Lapham GT, Hawkins EJ, Achtmeyer CE, Williams EC, Thomas RM: Quality concerns with routine alcohol screening in VA clinical settings. J Gen Intern Med 2010, 26:299-304.
• [32]Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA: The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998, 158:1789-1795.
• [33]Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME: Three questions can detect hazardous drinkers. J Fam Pract 2001, 50:313-320.
• [34]Saitz R: Alcohol screening and brief intervention in primary care: absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev 2010, 29:631-640.
• [35]Burge SK, Amodei N, Elkin B, Catala S, Andrew SR, Lane PA: An evaluation of two primary care interventions for alcohol abuse among Mexican-American patients. Addiction 1997, 92:1705-1716.
• [36]Chang G, Behr H, Goetz MA, Hiley A, Bigby J: Women and alcohol abuse in primary care. Identification and intervention. Am J Addict 1997, 6:183-192.
• [37]Sullivan LE, Tetrault JM, Braithwaite RS, Turner BJ, Fiellin DA: A meta-analysis of the efficacy of non-physician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home. Am J Addict 2011, 20:343-356.
• [38]Friedmann PD, McCullough D, Chin MH, Saitz R: Screening and intervention for alcohol problems: a national survey of primary care physicians and psychiatrists. J Gen Intern Med 2000, 15:84-91.
• [39]Saunders JB, Conigrave KM: Early identification of alcohol problems. Can Med Assoc J 1990, 143:1060-1069.
• [40]Broyles LM, Gordon AJ: SBIRT implementation: moving beyond the interdisciplinary rhetoric. Subst Abuse 2010, 31:221-223.
• [41]US Institute of Medicine: Health Professions Education: A Bridge to Quality. Washington, DC: National Academies of Science; 2003.
• [42]Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, on behalf of the Buprenorphine/Naloxone Collaborative Study Group: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349:949-958.
• [43]Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA: Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009, 37:426-430.
• [44]Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W: Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psych 2011, 68:1238-1246.
• [45]Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG: Counseling plus buprenorphine-naloxone maintenance for opioid dependence. N Engl J Med 2006, 355:365-374.
• [46]Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M: Collaborative care of opioid-addicted patients in primary care using buprenorphine. Arch Intern Med 2011, 171:425-432.
• [47]Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH: Office-based management of opioid dependence with buprenorphine: practices and barriers. J Gen Intern Med 2008, 23:1393-1398.
• [48]Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE: Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med 2008, 24:218-225.
• [49]Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y: Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program. Ann Intern Med 2010, 152:704-711.
• [50]Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL: Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
• [51]Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, on behalf of the BHIVES Collaborative: HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011, 56(1):S22-S32.
• [52]Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010, 12:CD001867.
• [53]Srisurapanont M, Jarusuraisin N: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005, 1:CD001867.
• [54]Lee JD, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D: Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat 2010, 39:14-21.
• [55]Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M: Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, 9:CD004332.
• [56]Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, on behalf of the COMBINE Study Research Group: Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
• [57]Wolwer W, Frommann N, Janner M, Franke PE, Scherbaum N, Lieb B: The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend 2011, 118:417-422.
• [58]Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, Weltman M, Haber P: Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 2008, 103:953-959.
• [59]Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H: A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008, 43:53-61.
• [60]Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I: Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psych 2011, 11:41. BioMed Central Full Text
• [61]Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ Jr: Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004, 28:295-301.
• [62]Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J: Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr 2010, 38:8-12.
• [63]Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG: Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103:2035-2044.
• [64]Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA: Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010, 34:1849-1857.
• [65]Flannery BA, Garbutt JC, Cody MW: Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004, 28:1517-1523.
• [66]Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.